ACE Report Cover
Lower 5-year wear with vitamin-E infused HXLPE liner versus standard crosslinked liner in THA
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
ARTHROPLASTY
Lower 5-year wear with vitamin-E infused HXLPE liner versus standard crosslinked liner in THA .

Evaluation of in vivo wear of vitamin E-diffused highly crosslinked polyethylene at five years

Bone Joint J. 2018 Dec;100-B(12):1592-1599. doi: 10.1302/0301-620X.100B12.BJJ-2018-0371.R1

208 patients (221 hips) scheduled for total hip arthroplasty were randomized to completion of surgery with either a vitamin E-infused highly crosslinked polyethylene liner (VEPE) or a moderately crosslinked polyethylene liner (ModXLPE). The primary purpose of this study was to compare liner wear via radiographic femoral head penetration between groups at 5-year follow-up. Results demonstrated significantly lower median total femoral head penetration in the VEPE group compared to the ModXLPE group at 5 years. When subgroup analyzed based on articulation type, the use of a ceramic femoral head demonstrated lower total liner wear relative to a metal femoral head within both groups. No patient in either group developed osteolysis or required revision for aseptic loosening. Clinical measures at 5 years, including pain and function, also did not significantly differ between groups.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Lower 5-year wear with vitamin-E infused HXLPE liner versus standard crosslinked liner in THA. ACE Report. 2019;8(1):4. Available from: https://myorthoevidence.com/AceReport/Show/lower-5-year-wear-with-vitamin-e-infused-hxlpe-liner-versus-standard-crosslinked-liner-in-tha

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report